Clinical efficacy of tumor antigen-pulsed dc treatment for high-grade glioma patients: Evidence from a meta-analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Cao, Jun Xia ^a,b   Zhang, Xiao Yan ^a   Liu, Jin Long ^a   Li, Duo ^a   Li, Jun Li ^a   Liu, Yi Shan ^a   Wang, Min ^a   Xu, Bei Lei ^a   Wang, Hai Bo ^a   Wang, Zheng Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; CYTOKINE;

ARTICLE; BRAIN SURGERY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD16+ T LYMPHOCYTE; CD3+ CD4+ T LYMPHOCYTE; CD3+ CD8+ T LYMPHOCYTE; CD56+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG EFFICACY; GLIOMA; HUMAN; HYPERTHERMIC THERAPY; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; ADULT; BRAIN NEOPLASMS; CANCER GRADING; DENDRITIC CELL; DISEASE FREE SURVIVAL; FEMALE; IMMUNITY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ADULT; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CYTOKINES; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; IMMUNITY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM GRADING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84933048332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107173     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2):97-109. Epub 2007 Jul 6.
2. Ruzevick J, Jackson C, Phallen J, Lim M (2012) Clinical trials with immunotherapy for high-grade glioma. Neurosurg Clin N Am. 23(3):459-470. doi: 10.1016/j.nec.2012.04.003. Epub 2012 Jun 8.
3. Badhiwala J, Decker WK, Berens ME, Bhardwaj RD (2013) Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Rev Neurother. 13(4):405-424. doi: 10.1586/ern.13.23.
4. Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest. 120(5):1368-1379. doi: 10.1172/JCI41911. Epub 2010 May 3.
5. Sagar D, Foss C, Baz ER, Pomper MG, Khan ZK, et al. (2012) Mechanisms of dendritic cell trafficking across the blood-brain barrier. J Neuroimmune Pharmacol. 7(1):74-94. doi: 10.1007/s11481-011-9302-7. Epub 2011 Aug 6.
6. Xu X, Stockhammer F, Schmitt M (2012) Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol. 2012:764213. doi: 10.1155/2012/764213. Epub 2012 Feb 28.
7. Fabry Z, Raine CS, Hart MN (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today. 15(5):218-224.
8. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 22;12(4):265-277. doi: 10.1038/nrc3258. Review.
9. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, et al. (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 54(4):519-525. doi: 10.1002/pbc.22319.
10. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, et al. (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 61(11):2033-2044. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.
11. De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, et al. (2012) Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother. 61(11):2105-2112. doi: 10.1007/s00262-012-1271-z. Epub 2012 May 8.
12. Van Gool S, De Vleeschouwer S (2012) Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients? Expert Rev Neurother. 12(10):1173-1176. doi: 10.1586/ern.12.107.
13. Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ (2013) Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev. 39(8):891-907. doi: 10.1016/j.ctrv.2013.05.007. Epub 2013 Jun 21.
14. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, et al. (2009) Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x.
15. Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. (2013) Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials. Neurol Med Chir (Tokyo). 53(11):741-754. Epub 2013 Oct 21.
16. Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, et al. (2014). Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol. 28;20(4):1095-1106. doi: 10.3748/wjg.v20.i4.1095.
17. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, et al. (2011) A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 18(8):1048-1054. doi: 10.1016/j.jocn.2010.11.034. Epub 2011 Jun 28.
18. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, et al. (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 11(11):4160-4167.
19. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 10(16):5316-5326.
20. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 11(15):5515-5525.
21. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, et al. (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 50(7):337-344.
22. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, et al. (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 89(7):1172-1179.
23. Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14):4973-4979.
24. Jie X, Hua L, Jiang W, Feng F, Feng G, et al. (2012) Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 62(1):91-99. doi: 10.1007/s12013-011-9265-6.
25. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, et al. (2012) Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg. 77(5-6):736-744. doi: 10.1016/j.wneu.2011.08.020. Epub 2011 Nov 7.
26. Van Gool S (2013) Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials. Immunotherapy. 5(10):1043-1046. doi: 10.2217/imt.13.86.
27. Shah AH, Bregy A, Heros DO, Komotar RJ, Goldberg J (2013) Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol. Neurosurgery. 73(5):863-867. doi: 10.1227/NEU. 0000000000000107.
28. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, et al. (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 108(5):963-971. doi: 10.3171/JNS/2008/108/5/0963.
29. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 28(31):4722-4729. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.
30. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331(6024):1565-1570. doi: 10.1126/science.1203486.
31. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, et al. (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14):5955-5964. doi: 10.1158/0008-5472.CAN-07-5973.
32. Hussain SF, Heimberger AB (2005) Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 5(5):777-790.
33. Ogbomo H, Cinatl J Jr, Mody CH, Forsyth PA (2011) Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol Med. 17(8):433-441. doi: 10.1016/j.molmed.2011.03.004. Epub 2011 Apr 19.
34. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell. 140(6):883-899. doi: 10.1016/j.cell.2010.01.025.
35. Jackson C, Ruzevick J, Brem H, Lim M. (2013) Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy. 5(2):155-167. doi: 10.2217/imt.12.155.
36. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, et al. (2013) An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 12(6):597-615. doi: 10.1586/erv.13.41.
37. Li Z, Lee JW, Mukherjee D, Ji J, Jeswani SP, et al. (2012) Immunotherapy targeting glioma stem cells-insights and perspectives. Expert Opin Biol Ther. 12(2):165-178. doi: 10.1517/14712598.2012.648180. Epub 2011 Dec 26.
38. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, et al. (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 17(6):1603-1615. doi: 10.1158/1078-0432.CCR-10-2563. Epub 2010 Dec 6.
39. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. (2011) Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011:732413. doi: 10.1155/2011/732413. Epub 2011 Dec 10.